Navigation Links
Novavax Reports Second Quarter 2009 Financial Results
Date:8/7/2009

oration; the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; our ability to obtain rights to technology; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; our ability to obtain adequate financing in the future through product licensing, co-promotional arrangements, public or private equity or debt financing or otherwise; general business conditions; competition; business abilities and judgment of personnel; and the availability of qualified personnel. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.

                                   NOVAVAX, INC.
                       CONSOLIDATED STATEMENTS OF OPERATIONS
               (in thousands, except share and per share information)
                                   (unaudited)

                                    Three months ended      Six months ended
                                        June 30,                June 30,
                                        --------                --------
                                    2009      2008          2009       2008
                                    ----      ----          ----       ----
    Revenues                           29        342           50         800
                                       --        ---           --         ---

    Operating costs and
     expenses:
       Research and development     5,297      5,380        9,563     
'/>"/>
SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Novavax Announces Appointment of Frederick W. Driscoll as Vice President, Chief Financial Officer and Treasurer
2. Novavax Announces Release Date of 2009 Second Quarter, Financial Results and Investor Conference Call
3. Novavax Announces Selection of a Respiratory Syncytial Virus Vaccine Candidate for Advanced Preclinical Studies
4. Novavax Announces Appointment of John J. Trizzino as Senior Vice President, International and Government Alliances
5. Novavax Announces Repayment of $5 Million of Convertible Debt
6. Cadila Pharmaceuticals Launches Joint Venture With Novavax in India
7. Spanish Government Selects Novavaxs VLP Technology for Comprehensive Flu Vaccine Solution in Spain
8. Novavax Appoints Stanley Erck to Board of Directors
9. Preclinical Proof-of-Concept Studies Published for Novavax Seasonal Influenza Virus-Like-Particle Vaccine
10. Novavax CEO to Present at Phacilitate Vaccine Forum Barcelona 2009
11. Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... , Feb. 26, 2015 S&P Capital IQ ... Stock Report coverage on MabVax Therapeutics Holdings Inc . ... a clinical stage biotechnology company focused on the development ... needs in the treatment of cancer. MabVax has discovered ... the protective immune responses generated by patients who have ...
(Date:2/26/2015)... N.J. , Feb. 26, 2015 On ... and its affiliated companies, Wilentz, Goldman & Spitzer, ... trade secrets lawsuit against Genewiz Inc. in excess of ... and utilized GenScript,s trade secrets, and that it improperly ... entered an order denying motions for judgment notwithstanding the ...
(Date:2/26/2015)...  23andMe, the leading personal genetics company, today announced ... Officer and Corporate Counsel. Black brings a strong background ... as health care regulations. As a member of the ... reviewing, updating and enhancing the company,s privacy and consent ... joined the company January 5, 2015 and reports to ...
(Date:2/26/2015)... , Feb. 26, 2015 /PRNewswire/ - SQI Diagnostics Inc. ... life sciences company that develops and commercializes proprietary technologies ... financial and operational results for the fiscal first quarter ... release are in Canadian dollars (CAD), unless otherwise stated. ... to win new business from our existing customers and ...
Breaking Biology Technology:S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 323andMe Appoints Kate Black as Privacy Officer and Corporate Counsel 2SQI Diagnostics Reports First Quarter Financial Results 2SQI Diagnostics Reports First Quarter Financial Results 3SQI Diagnostics Reports First Quarter Financial Results 4SQI Diagnostics Reports First Quarter Financial Results 5SQI Diagnostics Reports First Quarter Financial Results 6
... HONG KONG, April 27, 2012 /PRNewswire-Asia-FirstCall/ -- China Cord Blood ... Company"), the first and largest cord blood banking operator ... a US$65 million convertible debt financing with funds affiliated ... fund managed by Kohlberg Kravis Roberts & Co. L.P. ...
... April 26, 2012  Avaxia Biologics, Inc., a privately-held biotech ... antibody therapeutics for the treatment of gastrointestinal diseases, announced ... Chief Executive Officer of Arisaph Pharmaceuticals, Inc. to its ... that Chris has agreed to serve on our Board," ...
...  Sangamo BioSciences, Inc. (Nasdaq: SGMO ) today announced ... results on Wednesday, May 2, 2012, after the market closes. ... at 5:00 p.m. ET, which will be open to the ... company will review the financial results and discuss other business ...
Cached Biology Technology:China Cord Blood Corporation Announces Completion of $65 Million Convertible Debt Financing with KKR 2China Cord Blood Corporation Announces Completion of $65 Million Convertible Debt Financing with KKR 3Avaxia Biologics Elects Christopher Kiritsy to its Board of Directors 2Sangamo BioSciences Announces First Quarter 2012 Conference Call and Webcast 2
(Date:2/5/2015)... Carolina , 5. Februar 2015 /PRNewswire/ ... als spezialisiertes Logistikunternehmen und hat eine neue ... klinische Logistikfirma (Clinical Logistics Organization – CLO) ... neuen Kampagne lautet First , mit ... Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
(Date:2/5/2015)... -- New Market Research Reports Title Global ... 2020 has Been Added to GrandViewReseach.com Report Database ... reach USD 5.10 billion by 2020, according to a ... help identify the site of tissue damage in case ... in medical imaging applications. They have been extensively used ...
(Date:1/22/2015)... ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced the addition of ... to their offering. , The primary goal ... who she/he is claiming to be, and for this purpose, ... characteristics, such as fingerprint, hand or palm print, iris, face ...
Breaking Biology News(10 mins):Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3
... study presented today at the American College of Cardiology's ... that very intensive cholesterol lowering with a statin drug ... the coronary arteries. , This finding has ... drugs, the most commonly used cholesterol lowering treatment. Previous ...
... rate for the once almost universally fatal childhood cancer ... the near future, thanks to improvements in diagnosis and ... at St. Jude Children's Research Hospital. Almost 4,000 cases ... year, about two-thirds of which are in children and ...
... of a new study provide the first clear proof that ... is wiping out entire frog populations and driving many species ... the journal Nature, the study reveals how the warming may ... to amphibians. The climate-driven fungal disease, the author's say, has ...
Cached Biology News:Intensive statin therapy may partially reverse plaque build-up in arteries 2St. Jude projects 90 percent cure rate for ALL 2St. Jude projects 90 percent cure rate for ALL 3St. Jude projects 90 percent cure rate for ALL 4St. Jude projects 90 percent cure rate for ALL 5Climate change drives widespread amphibian extinctions 2
... Mouse monoclonal [YPF19] to Yersinia ... to detect Yersinia pestis . ... from Yersinia pestis vaccine ... This antibody recognises Y.pestis F1 capsular ...
Phospho-SEK1/MKK4 (Thr261) Antibody...
Rabbit polyclonal to Leucyl tRNA synthetase ( Abpromise for all tested applications). Antigen: L930-H1176 denatured human recombinant LRS. Entrez Gene ID: 3926 Swiss Protein ID: Q9P2J5...
Phospho-FADD (Ser194) Antibody (Human Specific)...
Biology Products: